Lucy Therapeutics
David is the Sokol Professor of Chemistry at Montclair State University where his NIH funded laboratory is actively engaged in drug discovery for CNS and parasitic disease. While in the pharmaceutical industry at Cephalon, Bristol Myers, and Wyeth he participated in and led programs in a variety of therapeutic areas that provided four clinical candidates for CNS, metabolic and cardiovascular disease.
This person is not in the org chart
This person is not in any offices
Lucy Therapeutics
Lucy Therapeutics is offering a differentiated and novel approach to drug discovery by drugging targets associated with early disease pathogenesis. LucyTx’s unique approach recognizes that improvement of mitochondrial function early in disease will lead to disease modification as opposed to late-stage symptomatic treatments being pursued by many others. Mitochondrial improvement effects multiple downstream effectors that are essential to disease initiation and progression. Our targets have been validated as neuroprotective in multiple animal models. Key to our strategy is a novel dosing regimen which will mimic effects known to be protective for both neurological and cardiovascular events implicated in key CNS diseases. LucyTx proposes to focus on the orphan disease Rett Syndrome for a proof of concept; we will also explore applications of our technology to Parkinson’s and other CNS diseases.